Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, France, Germany, Italy, Netherlands, Spain
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Myotonic Dystrophy|Myotonic Dystrophy Type 1
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VX24-670-101 | P2 |
Not yet recruiting |
Myotonic Dystrophy Type 1 |
2028-07-24 |
|
| Galileo | P2 |
Recruiting |
Myotonic Dystrophy Type 1 |
2026-12-01 |
|
| VX23-670-001 | P2 |
Recruiting |
Myotonic Dystrophy |
2025-11-30 |